Tamoxifen inhibits acidification in cells independent of the estrogen receptor
- 13 April 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (8) , 4432-4437
- https://doi.org/10.1073/pnas.96.8.4432
Abstract
Tamoxifen has been reported to have numerous physiological effects that are independent of the estrogen receptor, including sensitization of resistant tumor cells to many chemotherapeutic agents. Drug-resistant cells sequester weak base chemotherapeutics in acidic organelles away from their sites of action in the cytosol and nucleus. This work reports that tamoxifen causes redistribution of weak base chemotherapeutics from acidic organelles to the nucleus in drug-resistant cells. Agents that disrupt organelle acidification (e.g., monensin, bafilomycin A1) cause a similar redistribution. Measurement of cellular pH in several cell lines reveals that tamoxifen inhibits acidification of endosomes and lysosomes without affecting cytoplasmic pH. Similar to monensin, tamoxifen decreased the rate of vesicular transport though the recycling and secretory pathways. Organellar acidification is required for many cellular functions, and its disruption could account for many of the side effects of tamoxifen.Keywords
This publication has 62 references indexed in Scilit:
- Chronic Extracellular Acidosis Induces Plasmalemmal Vacuolar Type H+ ATPase Activity in OsteoclastsPublished by Elsevier ,1997
- Evidence for nonvectorial, retrograde transferrin trafficking in the early endosomes of HEp2 cells.The Journal of cell biology, 1995
- In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancerEuropean Journal Of Cancer, 1994
- Enhancement of Tamoxifen-Induced Suppression of Insulin-Like Growth Factor I Gene Expression and Serum Level by a Somatostatin AnalogueBiochemical and Biophysical Research Communications, 1994
- Tamoxifen is A Na+-Antagonistic Inhibitor of Na+/K+-Transporting ATPase from Tumour and Normal CellsJournal of Enzyme Inhibition, 1994
- Supplemental estrogen replacementCancer, 1994
- Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapyEuropean Journal Of Cancer, 1993
- Inhibition of melanoma cell/matrix interaction by tamoxifenMelanoma Research, 1993
- The antioxidant action of tamoxifen and its metabolites Inhibition of lipid peroxidationFEBS Letters, 1990
- The role of plasminogen activators in metastasisMedical Hypotheses, 1983